Dare Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Dare Bioscience, Inc. on January 8, 2018. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The registrant is incorporated in Delaware and identifies as an emerging growth company.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing discloses the posting of a corporate presentation to the company's website for use at investor and analyst meetings.
Guidance, Outlook, and Risks
The company intends to present the attached corporate presentation (Exhibit 99.1) at various investor and analyst meetings. The filing explicitly states that the information disclosed, including the presentation, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be incorporated by reference into any registration statement except as expressly set forth.
Key Facts for Investor Verification
- Verify the content of the corporate presentation attached as Exhibit 99.1, as the 8-K itself contains no financial data.
- Note that the presentation is not legally "filed" with the SEC and carries different liability standards than a formal filing.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.